Britain is battling an outbreak of the winter vomiting bug norovirus that's being fuelled by a new, highly transmissible form of the infection.

The Wyandotte woman had worked at Blue Cross for 32 years and was denied a religious accommodation to the insurer's vaccine ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

November 8, 2024) - Nationally recognized law firm Berger Montague PC informs investors that a lawsuit was filed against Metagenomi Inc. ("Metagenomi" or the "Company") (NASDAQ: MGX) on behalf of ...

Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Moderna (MRNA – Research Report) today and set a price ...

Health professionals recommend vaccines before traveling to celebrate the holidays with family. If you missed the early fall ...

The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

Moderna posted a surprising third-quarter profit, driven by cost-cutting and higher-than-expected Covid vaccine sales.

Moderna Inc.'s stock was higher but off its early highs Thursday, after the company's third-quarter earnings showed an unexpected profit as well as revenue that beat estimates by a wide margin. The ...

Moderna reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit for the period amid its efforts to cut costs and $1.8 billion in sales of ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.